Related Experiment Video
Updated: Jun 10, 2026

Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis
Published on: January 31, 2025
Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway
Xinna Zhang1, Guohui Wan, Sizolwenkosi Mlotshwa
1Department of Biological Sciences and Center for Colon Cancer Research, University of South Carolina, Columbia, SC 29208, USA.
Abstract:
Wild-type p53-induced phosphatase 1 (Wip1) was identified as an oncogene amplified and overexpressed in several human cancers. Recent evidence suggested that Wip1 is a critical inhibitor in the ATM/ATR-p53 DNA damage signaling pathway. Wip1 dephosphorylates several key DNA damage-responsive proteins and reverses DNA damage-induced cell cycle checkpoints. Previous reports showed that Wip1 was transcriptionally induced by p53 at the early stage of the DNA damage response. To investigate the temporal and functional regulation of Wip1, we identified a microRNA, miR-16, that specifically targets the mRNA of Wip1 and thus negatively regulates the expression level of Wip1. miR-16 itself is induced immediately after DNA damage. Therefore, the increase in Wip1 protein level is significantly postponed compared with that of its mRNA level, preventing a premature inactivation of ATM/ATR signaling and allowing a functional completion of the early DNA damage response. To better understand miR-16 biological functions in the context of cancer cells, we examined its expression in mammary tumor stem cells and found it to be markedly downregulated in mammary tumor stem cells. Overexpression of miR-16 or inhibition of Wip1 suppresses the self-renewal and growth of mouse mammary tumor stem cells and sensitizes MCF-7 human breast cancer cells to the chemotherapeutic drug doxorubicin. Together, our results suggest an important role of miR-16 in the regulation of Wip1 phosphatase in the DNA damage response and mammary tumorigenesis.
Insights
MicroRNA-16 (miR-16) regulates Wild-type p53-induced phosphatase 1 (Wip1) expression, impacting DNA damage response and mammary tumorigenesis. Downregulation of miR-16 in cancer stem cells promotes tumor growth and chemoresistance.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- Wild-type p53-induced phosphatase 1 (Wip1) is an oncogene overexpressed in cancers, inhibiting ATM/ATR-p53 DNA damage signaling.
- Wip1 dephosphorylates DNA damage proteins, reversing cell cycle checkpoints and is transcriptionally induced by p53.
Purpose of the Study:
- To investigate the temporal and functional regulation of Wip1.
- To identify regulatory mechanisms of Wip1 in DNA damage response and mammary tumorigenesis.
Main Methods:
- Identification of microRNA-16 (miR-16) as a negative regulator of Wip1 mRNA.
- Analysis of miR-16 induction kinetics post-DNA damage.
- Examination of miR-16 expression in mammary tumor stem cells.
- Assessment of miR-16 or Wip1 inhibition effects on mammary tumor stem cell self-renewal and growth.
- Evaluation of miR-16 effects on breast cancer cell chemosensitivity.
Main Results:
- miR-16 directly targets and downregulates Wip1 expression.
- miR-16 is induced immediately after DNA damage, delaying Wip1 protein increase and ensuring functional DNA damage response.
- miR-16 is downregulated in mammary tumor stem cells.
- Overexpression of miR-16 or Wip1 inhibition suppressed mammary tumor stem cell growth and enhanced chemosensitivity.
Conclusions:
- miR-16 plays a crucial role in regulating Wip1 phosphatase during DNA damage response.
- Dysregulation of the miR-16/Wip1 axis contributes to mammary tumorigenesis and chemoresistance.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
